1. Home
  2. CRSP vs MNSO Comparison

CRSP vs MNSO Comparison

Compare CRSP & MNSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • MNSO
  • Stock Information
  • Founded
  • CRSP 2013
  • MNSO 2013
  • Country
  • CRSP Switzerland
  • MNSO China
  • Employees
  • CRSP N/A
  • MNSO N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • MNSO Department/Specialty Retail Stores
  • Sector
  • CRSP Health Care
  • MNSO Consumer Discretionary
  • Exchange
  • CRSP Nasdaq
  • MNSO Nasdaq
  • Market Cap
  • CRSP 5.4B
  • MNSO 6.0B
  • IPO Year
  • CRSP 2016
  • MNSO 2020
  • Fundamental
  • Price
  • CRSP $54.26
  • MNSO $25.16
  • Analyst Decision
  • CRSP Buy
  • MNSO Buy
  • Analyst Count
  • CRSP 16
  • MNSO 4
  • Target Price
  • CRSP $72.27
  • MNSO $25.00
  • AVG Volume (30 Days)
  • CRSP 2.9M
  • MNSO 1.1M
  • Earning Date
  • CRSP 08-04-2025
  • MNSO 08-21-2025
  • Dividend Yield
  • CRSP N/A
  • MNSO 2.45%
  • EPS Growth
  • CRSP N/A
  • MNSO N/A
  • EPS
  • CRSP N/A
  • MNSO 1.06
  • Revenue
  • CRSP $38,050,000.00
  • MNSO $2,600,350,931.00
  • Revenue This Year
  • CRSP $28.31
  • MNSO $24.36
  • Revenue Next Year
  • CRSP $268.05
  • MNSO $18.27
  • P/E Ratio
  • CRSP N/A
  • MNSO $25.21
  • Revenue Growth
  • CRSP N/A
  • MNSO 21.03
  • 52 Week Low
  • CRSP $30.04
  • MNSO $12.51
  • 52 Week High
  • CRSP $71.13
  • MNSO $27.71
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 45.78
  • MNSO 82.43
  • Support Level
  • CRSP $51.80
  • MNSO $19.95
  • Resistance Level
  • CRSP $61.44
  • MNSO $20.88
  • Average True Range (ATR)
  • CRSP 2.79
  • MNSO 0.57
  • MACD
  • CRSP -0.79
  • MNSO 0.48
  • Stochastic Oscillator
  • CRSP 26.14
  • MNSO 99.17

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About MNSO MINISO Group Holding Limited

MINISO Group Holding Ltd is a value retailer offering a variety of trendy lifestyle products featuring IP design. The principal activity of the Company is investment holding. The company's product categories include home decor, small electronics, textiles, accessories, beauty tools, toys, cosmetics, personal care, snacks, fragrance and perfumes, and stationery and gifts. Its segment includes the MINISO brand, which is engaged in the Design, buying, and sale of lifestyle products, and the TOP TOY brand, which is engaged in the Design, buying, and sale of pop toys. The company generates maximum revenue from the MINISO brand segment. Geographically, it derives a majority of its revenue from China.

Share on Social Networks: